We are live on ! Find out more
IBER

Ibere Pharmaceuticals
IBER

Delisted

IBER was delisted on the 1st of March, 2023.

Back to rankings

32 hedge funds and large institutions have $61.1M invested in Ibere Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 32 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
32
Holders Change
+32
Holders Change %
–
% of All Funds
0.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
32
Increased
–
Reduced
–
Closed
–
Calls
$74K
Puts
–
Net Calls
+$74K
Net Calls Change
+$74K

Top Buyers

Rank Fund Capital Flow
1
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$6.05M
2
Citadel Advisors
Citadel Advisors
Florida
+$5.35M
3
PAMP
Polar Asset Management Partners
Ontario, Canada
+$4.87M
4
LA
Linden Advisors
New York
+$4.38M
5
Marshall Wace
Marshall Wace
United Kingdom
+$4.38M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Hudson Bay Capital Management
1
Hudson Bay Capital Management
Connecticut
$6.01M +$6.05M +621,750 New
Citadel Advisors
2
Citadel Advisors
Florida
$5.32M +$5.35M +550,097 New
PAMP
3
Polar Asset Management Partners
Ontario, Canada
$4.83M +$4.87M +500,000 New
Marshall Wace
4
Marshall Wace
United Kingdom
$4.35M +$4.38M +449,994 New
LA
5
Linden Advisors
New York
$4.35M +$4.38M +450,000 New
SC
6
Sculptor Capital
New York
$4.11M +$4.14M +425,000 New
SCC
7
Spring Creek Capital
Kansas
$3.87M +$3.89M +400,000 New
VI
8
Vestcor Inc
New Brunswick, Canada
$3.87M +$3.89M +400,000 New
MCM
9
Moore Capital Management
New York
$2.9M +$2.92M +300,000 New
RCM
10
Radcliffe Capital Management
Pennsylvania
$2.9M +$2.92M +300,000 New
Nomura Holdings
11
Nomura Holdings
Japan
$2.75M +$2.76M +283,686 New
Millennium Management
12
Millennium Management
New York
$2.24M +$2.26M +231,990 New
MP
13
Mangrove Partners
Connecticut
$1.93M +$1.95M +200,000 New
PMAM
14
Picton Mahoney Asset Management
Ontario, Canada
$1.93M +$1.95M +200,000 New
Wells Fargo
15
Wells Fargo
California
$1.62M +$1.63M +167,484 New
Alyeska Investment Group
16
Alyeska Investment Group
Illinois
$1.45M +$1.46M +150,000 New
FTCM
17
Fir Tree Capital Management
New York
$795K +$800K +82,200 New
AA
18
AQR Arbitrage
Connecticut
$725K +$730K +75,000 New
WA
19
Whitebox Advisors
Minnesota
$725K +$730K +75,000 New
OPU
20
Omni Partners US
California
$717K +$721K +74,143 New
WRBC
21
W.R. Berkley Corp
Connecticut
$666K +$669K +68,776 New
Goldman Sachs
22
Goldman Sachs
New York
$530K +$533K +54,762 New
PI
23
PEAK6 Investments
Illinois
$484K +$487K +50,000 New
AM
24
Ampfield Management
New York
$431K +$433K +44,543 New
DMK
25
David M. Knott
$348K +$350K +36,000 New
1
2

IBER Hedge Fund Activity: Q2 2021 in Review

32 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals (IBER) for Q2 2021, worth a combined $61.1M.

Buyers outnumbered sellers: 32 funds opened new IBER positions and 0 closed out — a net gain of 32 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $6.05M.

  • 32 institutional investors held Ibere Pharmaceuticals (IBER) as of Q2 2021, up from 0 in Q1 2021.
  • Funds reported $61.1M of Ibere Pharmaceuticals stock for Q2 2021.
  • 32 funds opened new Ibere Pharmaceuticals positions in Q2 2021 and 0 closed out, a net change of +32 holders.
  • The largest Ibere Pharmaceuticals buyer in Q2 2021 was Hudson Bay Capital Management, an estimated $6.05M added.

Based on aggregated 13F filings for Q2 2021.